Cellares logo

Cellares

Accelerating Access to Life-Saving Cell Therapies

332 employees · est. 2019 · South San Francisco, United...

VS
SCTbio logo

SCTbio

Unparalleled Expertise and Seamless Solutions for Advanced Therapies and Viral Vector Manufacturing

45 employees · est. 2021 · Praha, Czech Republic

Cellares is the older company (2019 vs 2021); Cellares is the larger of the two.

Side-by-Side Comparison

Cellares SCTbio
Founded
2019 older 2021
Headquarters
South San Francisco, United States Praha, Czech Republic
Employees
332 larger 45
Industry
Biotechnology, Pharmaceutical Health Care
Funding Stage
Series D Not tracked yet
Total Funding
$612.00M Not tracked yet
Funding Rounds
4 Not tracked yet
Services
Cell Shuttle® Platform, Cell Q™ Platform, Clinical & Commercial Manufacturing, Analytical Method Automation, Process Automation, Quality and Regulatory Consultation Not tracked yet
Target Customers
Biopharmaceutical Companies, Cell Therapy Developers, Pharmaceutical Companies Not tracked yet
Taxonomy
Integrated Development And Manufacturing Organization, Cell Therapy, Industry 4.0, Automated Manufacturing, Cell Shuttle, Cell Q, Smart Factories, Advanced Manufacturing Technology, FDA Compliance, Oncology, Autoimmune Indications, Clinical Manufacturing, Process Automation, Scalable Manufacturing, Cost Reduction Cell Therapy, Gene Therapy, PPF Biotech Network, SOTIO Biotech, Contract Manufacturing, GMP Services, Advanced Therapy Medicinal Products, ATMPs, Genetically Modified, Viral Vectors, Biotech, Pharmaceutical, Regenerative Medicine
Website
cellares.com sctbio.com
Cellares logo

About Cellares

Cellares, founded in 2019 and headquartered in the United States, is at the forefront of revolutionizing cell therapy manufacturing. As the first Integrated Development and Manufacturing Organization (IDMO), Cellares delivers on its promise of "Accelerating Access to Life-Saving Cell Therapies" by d...

SCTbio logo

About SCTbio

SCTbio, a part of the PPF Biotech network and sister company of SOTIO Biotech, is a standalone contract manufacturing organization focused on accelerating the production of Advanced Therapy Medicinal Products (ATMPs), including genetically modified and viral vectors. Founded in 2021, SCTbio aims to...

We will tell you when either one moves

BounceWatch watches Cellares and SCTbio for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Cellares and SCTbio — by email.

Frequently Asked Questions

Cellares — Accelerating Access to Life-Saving Cell Therapies. SCTbio — Unparalleled Expertise and Seamless Solutions for Advanced Therapies and Viral Vector Manufacturing. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Cellares has raised $612.00M while SCTbio has raised undisclosed funding.
Cellares and SCTbio operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Cellares with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Cellares on 15 Jun 2026, and SCTbio on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy